Introduction
Leukemic cells from most patients with chronic myelogenous leukemia (CML) and some patients with acute lymphocytic leukemia (ALL) contain the Philadelphia (Ph 1 ) chromosome (Clark et al., 1989; Kurzrock et al., 1988) . This chromosome is the result of a translocation that fuses part of the breakpoint cluster region gene (bcr) on chromosome 22 upstream of the gene for the Abelson tyrosine kinase (abl) on chromosome 9. The fusion produces the bcr-abl oncogene whose gene product, Bcr-Abl, is believed to be the causative agent of Ph 1 -positive leukemias (Daley et al., 1990) . Depending on the point of chromosomal fusion, three Bcr-Abl proteins can be produced. A 210 kDa Bcr-Abl protein is associated with CML while a 185 kDa Bcr-Abl protein is found in a subset of ALL cases (Clark et al., 1989; Kurzrock et al., 1987) . A rare 230 kDa Bcr-Abl protein has been observed in cells from patients with chronic neutrophilic leukemia (CNL) (Pane et al., 1996; Wada et al., 1995) .
The mechanisms by which Bcr-Abl signals to cause transformation are actively under investigation. BcrAbl is a constitutively active tyrosine kinase that transforms cells of both ®broblast and hematopoietic origin in cell culture systems (Young and Witte, 1988; McLaughlin et al., 1987; Daley and Baltimore, 1988) . Bcr-Abl inhibits apoptosis induced by cytokine deprivation, DNA damage, and a variety of chemotherapeutic agents (Bedi et al., 1994 (Bedi et al., , 1995 Kabarowski et al., 1994; Laneuville et al., 1994; McGahon et al., 1994; Sanchez-Garcia and Grutz, 1995; Smetsers et al., 1994) . However, Bcr-Abl does not prevent apoptosis induced by natural killer cells or in response to X-irradiation in some cell types (Amos et al., 1995; Roger et al., 1996) . The ability of Bcr-Abl to block apoptosis is dependent on its ability to activate Ras (Cortez et al., 1996) . In addition, some Bcr-Abl-transformed cells have been shown to contain elevated Bcl-2 expression (Sanchez-Garcia and Grutz, 1995) .
Although the ability of Bcr-Abl to inhibit apoptosis is likely to be an important component of its transforming activity, several lines of evidence suggest that Bcr-Abl may also signal to aect cell proliferation. Chronic phase CML cells retain the capacity to dierentiate, but they appear to undergo extra cycles of cell division as they mature and thus may have an increased proliferative capacity compared to normal cells (Clarkson and Strife, 1993) . Ph 1 -positive ALL cells expressing Bcr-Abl exhibit a proliferative advantage suggesting that p185 Bcr-Abl stimulates mitogenic pathways in these cells (Ribeiro et al., 1987) . Expression of Bcr-Abl in cytokine-dependent hematopoietic cells allows for cytokine independent proliferation in the absence of autocrine production of growth factors (Carlesso et al., 1994; Cortez et al., 1995; Laneuville et al. 1994) . Bcr-Abl activates Ras, which is required for mitogenic signal transduction in response to extracellular growth factors in multiple cell types (Pendergast et al., 1993b; Mandanas et al., 1993; Cortez et al., 1995) . Two explanations could account for these observations that link Bcr-Abl expression to increased proliferation. First, the Bcr-Abl-associated cell proliferation may not be a primary consequence of Bcr-Abl signaling. According to this model, the antiapoptotic activity of Bcr-Abl could promote the accumulation of additional genetic abnormalities which cause cell proliferation. Therefore, the transforming activity of Bcr-Abl could be similar to molecules like Bcl-2 or the E2A-HLF chimeric transcription factor (Inaba et al., 1996; Korsmeyer, 1992; Tsujimoto et al., 1984 Tsujimoto et al., , 1985 . This model has been supported by experiments with a temperature sensitive Bcr-Abl protein expression in hematopoietic cells, as well as some experiments in ®broblast cell types (Kabarowski et al., 1994; Renshaw et al., 1995) . Alternatively, the Bcr-Abl tyrosine kinase may directly activate mitogenic signaling pathways and drive cell cycle progression. To distinguish between these two hypotheses, we developed a system for regulating the expression of Bcr-Abl that allows analysis of its primary eects in myeloid progenitor cells. Using this system we show that both p185 and p210 Bcr-Abl directly activate mitogenic pathways and stimulate cell cycle progression. These data demonstrate for the ®rst time that Bcr-Abl concomitantly deregulates cell growth and inhibits apoptosis.
Results

Expression of Bcr-Abl in IL-3-dependent, 32D cells causes immediate IL-3-independent proliferation
We have previously demonstrated that 32D cells provide a model system for Bcr-Abl transformation . 32D cells are untransformed, diploid, murine, myeloid progenitor cells that depend on interleukin (IL)-3 for both growth and viability. In the absence of IL-3, 32D cells rapidly die by an apoptotic mechanism (Collins et al., 1992) . Bcr-Abl expression inhibits apoptosis and causes IL-3-independent proliferation of these cells . It has been previously suggested that the IL-3-independent proliferation associated with hematopoietic cell lines transfected with p210 Bcr-Abl requires prolonged exposure to the activated tyrosine kinase (greater than 2 weeks) (Kabarowski et al., 1994) . In contrast, we found that we could derive IL-3 independent cells by infection with Bcr-Abl retroviruses and subsequent removal of IL-3 (Figure 1 ). Selection of Bcr-Abl expressing cells by removal of IL-3 was more ecient than selection for the neomycin resistance gene present in the retroviral vector that drives Bcr-Abl expression. Only a small lag was observed in the growth of the cells at the start of selection which corresponded to the elimination of non-infected cells. Exponentially growing IL-3-independent cells are obtained within 48 h of selection. The tyrosine kinase activity of Bcr-Abl is required to elicit this IL-3-independent growth. Proliferating cells expressing Bcr-Abl proteins that lack tyrosine kinase activity could only be selected for with G418 in the presence of IL-3 (Figure 1 ). These results indicate that growth factor independent proliferation does not require prolonged exposure to the activated Bcr-Abl tyrosine kinase activity. Similar results were obtained in BaF3 and DAGM cells which also require IL-3 for growth and viability (data not shown).
Bcr-Abl activates extracellular signal-regulated kinases (Erk) in 32D cells
To test whether the growth factor independent proliferation was associated with activation of mitogenic signaling pathways, we examined the activation state of the Erk family of mitogen-activated protein (Map) kinases after infection with retroviruses encoding Bcr-Abl. This family is a well known participant in mitogenic signaling pathways elicited by extracellular stimulation (Cobb and Goldsmith, 1995; Kortenjann and Shaw, 1995) . Infection of 32D cells with retroviruses encoding Bcr-Abl resulted in the activation of Erk2, as measured by the electrophoretic mobility shift of activated Erk (Figure 2a ). Control retroviruses that do not encode Bcr-Abl do not cause Erk activation (data not shown). Erk activation declines over time after the initial activation. This is probably due to feedback pathways, such as induction of Map kinase phosphatases, that are turned on to control the activation state of the pathway (Sun et al., 1993; Ward et al., 1994) . However, 32D, DAGM, and BaF3 cells stably transformed by Bcr-Abl and maintained in long term culture contain constitutive increased levels of Erk activation (Figure 2b and data not shown). This activation was con®rmed by in vitro kinase assays (Figure 2b ). Together, these data strongly suggest that Bcr-Abl induces growth factor independent proliferation and activates mitogenic signaling pathways as primary consequences of expression in myeloid progenitor cells.
Cells stably expressing Bcr-Abl fail to growth arrest following growth factor starvation and maintain elevated cyclin-Cdk activities Bcr-Abl expression does not alter the proliferative rate of 32D cells or change the distribution of cells in the cell cycle under high serum conditions (Figure 1 and data not shown). To further study the eects of BcrAbl signaling on the growth properties of 32D cells we developed growth conditions that cause 32D cells to reversibly growth arrest. Growing cells in 1% fetal bovine serum and 0.1 ± 0.5% of WEHI-conditioned media as a source of IL-3 (see Materials and methods) induced 32D cells to growth arrest with unreplicated DNA without undergoing apoptosis (Figure 3 ). These growth factor starved cells are most likely arrested in G 0 because stimulation with serum and IL-3 induces S phase entry after 14 h (Figure 3) . Proliferating 32D cells grown in high serum and IL-3 have a doubling time of approximately 16.2+1.6 (mean+s.d.) h (Figure 1) , and the length of an entire G1 phase in proliferating cells is less than 8 h.
32D cells stably expressing the kinase-inactive forms of Bcr-Abl accumulate with unreplicated DNA (Table  1 ) and do not increase in cell number (data not shown) when grown in these low serum and IL-3 conditions for 24 h. However, cells expressing the wild type Bcr- Figure 1 Infection of 32D cells with Bcr-Abl retroviruses causes IL-3 independent proliferation. 32D cells were infected with retroviruses containing the wild type or tyrosine kinase inactive (KR) p210 Bcr-Abl genes. Selection was performed by either addition of G418 (Ð) or by IL-3 deprivation (---) 36 h after infection. Viable cell number was assessed by trypan blue exclusion at the indicated times post-infection Abl proteins continue to cycle under the reduced serum and IL-3 conditions (Table 1) . Therefore, hematopoietic cells expressing the Bcr-Abl oncogene exhibit reduced growth factor requirements for cell cycle progression.
The ability of 32D cells expressing Bcr-Abl to continue to cycle under low growth factor conditions suggested that Bcr-Abl signaling may maintain the activation of components of the cell cycle machinery which control the G1-to-S phase transition. The activities of cyclin-dependent kinases including D2-and D3-associated Cdk4 and Cdk6 decrease rapidly in 32D cells grown in reduced growth factor conditions ( Figure 4 , lanes 2 and 6). However, even under reduced growth factor conditions, Bcr-Abl expression maintains the activity of these kinases to levels that are similar to those observed with growth factor stimulation ( Figure 4 , lanes 3, 4, 7 and 8). . Cell lysates were analysed by Western blotting with anti-Raf and anti-Erk antibodies. Erk activity was measured by an in vitro immune-complex kinase assay using myelin basic protein as a substrate Figure 3 Reversible cell cycle arrest elicited by growth factor deprivation. 32D cells were starved for IL-3 and serum for 32 h. 10% serum and 10% WEHI-conditioned media were added to the culture and cell aliquots were removed and stained with propidium iodide for FACS analysis at the indicated times
Anti-D3 Anti-D2 Figure 4 Bcr-Abl expression allows constitutive activation of cyclin-dependent kinases. Parental 32D cells (lanes 2 and 6) and 32D cells expressing p185 Bcr-Abl (lanes 1, 4, 5 and 8) were starved for growth factors for 24 h. Growth factor starved 32D cells that were subsequently stimulated with 10% serum and 10% WEHI-conditioned media for 16 h were also examined (lanes 3 and 7). Equal amounts of cell lysate were immunoprecipitated with control IgG (lanes 1 and 5), cyclin D3 (lanes 2 ± 4), or cyclin D2 (lanes 6 ± 8) antibodies. Associated kinase activities were determined in an in vitro kinase assay using GST-Rb as a substrate
Cyclin D1 is not expressed in 32D cells and no associated kinase activity was detected in D1 immunoprecipitates (data not shown). These analysis show that Bcr-Abl signaling can prevent cells from exiting the cell cycle and prevent the down regulation of mitogenic signaling pathways by growth factor deprivation.
Inducible expression of Bcr-Abl in 32D myeloid progenitor cells
A system to regulate Bcr-Abl activity or expression is required to examine if Bcr-Abl is capable of inducing quiescent cells to re-enter the cell cycle. We derived clonal 32D cell lines that inducibly express the p210 or p185 forms of Bcr-Abl from a glucocorticoidresponsive promoter. These cells have no detectable expression of Bcr-Abl in the absence of inducing agent ( Figure 5a , lane 1). In addition, removal of IL-3 resulted in the complete loss of viability similar to that observed with parental 32D cells indicating the absence of functional Bcr-Abl protein (data not shown).
Treatment of these lines with dexamethasone induces accumulation of Bcr-Abl protein ( Figure 5a ). Antiphosphotyrosine Western blot analysis of total cell lysates of 32D cells induced to express p185 Bcr-Abl shows the accumulation of phosphotyrosine-containing proteins concomitant with the induction of the activated tyrosine kinase ( Figure 5b ). As early as 6 h after dexamethasone addition there is an increase in the phosphotyrosine content of proteins with apparent molecular weight of 190 kD (p185 Bcr-Abl), 152 kD, 120 kD, 85 kD, and 62 kD. Similar results were observed with clones expressing p210 Bcr-Abl. Only 25 nM of dexamethasone was required for optimal BcrAbl induction, and no toxicity was observed even at 20-fold higher concentrations. Therefore, this system provides an excellent means of analysing the initial eects of Bcr-Abl expression in myeloid progenitor cells.
Inducible expression of Bcr-Abl de®nes initial signaling events elicited by Bcr-Abl expression
The ability of Bcr-Abl to activate mitogenic signaling pathways was investigated using this inducible expression system. Inducible expression of Bcr-Abl caused an increase in the levels of active, GTP-bound Ras and hyperphosphorylation of Raf (Figure 6a and c). Erk activation was con®rmed by measuring Erk activity directly in an in vitro immune-complex kinase assay ( Figure 6d ). In addition, the Jun amino-terminal (Jnk) family of Map kinases became activated by Bcr-Abl expression, in agreement with a previous report ( Figure  6e ) (Raitano et al., 1995 
Bcr-Abl is sucient to induce G1-to-S-phase progression
To determine if Bcr-Abl expression was sucient to induce quiescent cells to reenter the cell cycle, the BcrAbl inducible cells were starved for growth factors as described for Figure 3 and Table 1 . Induction of p210 or p185 Bcr-Abl protein expression in growth factor arrested cells elicits an increase in DNA synthesis 30 h after dexamethasone addition, while dexamethasone has no eect on control cells (Figure 7a ). The eect of Bcr-Abl expression on cell cycle distribution was also monitored by¯ow cytometric analysis of DNA content. Cells were plated in low serum and reduced IL-3 conditions at time zero and dexamethasone was Figure 7b also shows that apoptosis (cells with less than 2N DNA content) is not appreciable during the experiment. Therefore, Bcr-Abl is sucient to drive G1-to-S phase progression in 32D myeloid progenitor cells under reduced serum and cytokine conditions.
Bcr-Abl expression activates Cdk2
We next examined the activity of Cdk2 to con®rm that the cell cycle entry induced by Bcr-Abl is associated with activation of the cell cycle machinery. Cdk2 associates with cyclin E at the G1/S phase transition and is required for S phase entry (Ko et al., 1992; Tsai et al., 1993) . We monitored Cdk2 activity after induction of Bcr-Abl in cells arrested by growth factor starvation. Cdk2 activity increases after p210 Bcr-Abl expression is induced (Figure 7c ). Cdk2 activation corresponds to the timing of S phase entry which occurred approximately 30 h after dexamethasone addition (see Figure 7b ). 32D cells express two alternatively spliced forms of Cdk2 (33 and 38 kDa) (Kato and Sherr, 1993) . There is no change in the expression level of the two alternatively spliced Cdk2 proteins after Bcr-Abl expression (Figure 7c ), and dexamethasone does not alter Cdk2 activity in control cells (data not shown). In similar experiments, we also observed activation of cyclin D2 and D3 associated kinases (data not shown) con®rming that the cell cycle entry observed after Bcr-Abl expression is accompanied by activation of the cell cycle machinery.
Discussion
This study shows that Bcr-Abl activates mitogenic signaling pathways and stimulates the G1-to-S transition in growth factor starved hematopoietic cells. Our experiments failed to distinguish any dierence between the signaling and transforming abilities of p185 and p210 Bcr-Abl in cultured cells even though the diseases associated with these Bcr-Abl proteins exhibit dierent clinical phenotypes. Both p185 and p210 caused immediate IL-3 independent proliferation of 32D cells, prevented cell cycle exit and maintained cyclin-D-associated kinase activities after growth factor deprivation, activated Ras, Erk and Jnk, and stimulated re-entry into the cell cycle. Small quantitative variations were evident in some experiments (see Figure 7a for example). However, clonal variation between dierent isolates of cell lines was greater than the variation between p185 and p210. Our data supports the hypothesis that Bcr-Abl causes transformation in part by activating mitogenic signaling pathways. This conclusion is also supported by studies showing that dominant interferring mutants of Grb2, Ras, c-Myc and c-Jun block Bcr-Ablmediated transformation (Cortez et al., 1996; Gishizky et al., 1995; Raitano et al., 1995; Sawyers et al., 1992 Sawyers et al., , 1995 . Grb2, Ras and c-Jun are components of the same pathway, and the ®nding that all three are required for Bcr-Abl signaling emphasizes the impor- No Dex Dex at T=20 h c tance of the Ras pathway in the transmission of the biological eects of Bcr-Abl. We propose that the BcrAbl tyrosine kinase recruits multiple intracellular signaling pathways that allow it to concomitantly inhibit apoptosis and induce cell proliferation, and in this manner to elicit tumorigenic growth of hematopoietic cells. The novel Bcr-Abl inducible system described here provides a method of regulating the expression of BcrAbl, and thus allows the analysis of signaling pathways activated by Bcr-Abl in hematopoietic cells. This system was required to determine if Bcr-Abl could stimulate re-entry of quiescent cells into S phase since stable expression of Bcr-Abl prevented cell cycle exit after growth factor deprivation. Interestingly, S phase entry via induction of Bcr-Abl protein requires incubation with dexamethasone for approximately 30 h (Figure 7 ) even though some Bcr-Abl protein is detectable within 6 h ( Figure 5 ). Serum and IL-3 stimulation of the same cells after growth factor arrest results in a synchronous re-entry into the cell cycle after approximately 14 h of treatment (Figure 3) . The 16 h dierence between the time it takes Bcr-Abl (i.e. dexamethasone addition) to stimulate S phase entry compared with serum/IL-3 is consistent with a need for accumulation of a threshold level of Bcr-Abl expression to begin signaling. Indeed, while IL-3 and serum activate Ras and Erk within minutes of treatment, we ®rst observe Ras and Erk activation about 12 h after dexamethasone addition (Figure 6 ). The Bcr-Ablstimulated re-entry into the cell cycle also appears to be asynchronous (Figure 7 ). This may be because individual cells within the population accumulate BcrAbl protein at dierent rates or accumulate dierent levels of Bcr-Abl protein. Nevertheless, our data show that Bcr-Abl is capable of activating mitogenic signaling pathways which lead to activation of the cell cycle machinery, induction of DNA synthesis and cell cycle progression in growth factor starved hematopoietic cells.
In apparent contrast to the results presented here, several reports have suggested that Bcr-Abl does not activate mitogenic signaling pathways to cause transformation (Kabarowski et al., 1994; Renshaw et al., 1995) . Using a temperature-sensitive Bcr-Abl mutant, Kabarowski and coworkers found that the primary eect of Bcr-Abl in hematopoietic cells is to inhibit apoptosis. They concluded that Bcr-Abl does not activate mitogenic signaling pathways in hematopoietic cells (Kabarowski et al., 1994) . Unfortunately, Ras activity was not measured to determine if the temperature-sensitive Bcr-Abl mutant could activate a known downstream target of wild type Bcr-Abl. Several possibilities could account for the discrepancies between our data and this report. The mutations of the tyrosine kinase domain which were introduced to achieve temperature sensitivity could alter substrate recognition or speci®city. In addition, aberrant cell culture temperatures, which may aect various signaling pathways independent of Bcr-Abl expression, were used to activate the mutated tyrosine kinase. Finally, the levels of active Bcr-Abl kinase following switch to the permissive temperature may not have been sucient for complete activation of signaling pathways. Our data support the idea that there is a threshold level of Bcr-Abl expression that must be surpassed to initiate mitogenic signal transduction cascades. Figures 2 and 6 show that when Bcr-Abl is expressed at approximately equal levels to endogenous c-Abl, there is no detectable increase in Erk activity. Only when higher levels of Bcr-Abl protein accumulates does Erk become activated. Increased Bcr-Abl protein levels may facilitate ecient oligomerization of Bcr-Abl which has been shown to be important for biological activity (McWhirter et al., 1993) . It is also interesting to note that the migration of Bcr-Abl protein on SDS ± PAGE gels decreases as more protein is expressed ( Figure 5 ). This may be the result of additional phosphorylation events that occur as a threshold level of Bcr-Abl protein is surpassed.
The ability of Bcr-Abl to activate mitogenic signaling pathways has also been assessed in NIH3T3 cells. Bcr-Abl was shown to alleviate the anchorage dependence of these cells for growth (Renshaw et al., 1995) . Anchorage has recently been shown to be critical for Cdk2 activation in ®broblasts (Fang et al., 1996) . Thus, our results showing that Bcr-Abl signaling leads to the activation of Cdk2 provides one mechanistic explanation for the ability of Bcr-Abl to cause anchorage independent growth of these cells. However, the authors of this study were unable to detect stimulation of DNA synthesis or growth in soft agar when the Bcr-Abl expressing NIH3T3 cells were grown in 0.5% serum. In addition, transcriptional reporter assays failed to detect Ras-dependent transcriptional activation by Bcr-Abl. Therefore, the authors concluded that Bcr-Abl does not activate mitogenic signaling pathways in NIH3T3 cells. In contrast, we previously demonstrated that Bcr-Abl does activate Ras-dependent transcriptional activation when transiently expressed in NIH3T3 cells (Pendergast et al., 1993a) . The contradictory results using reporter assays highlight the need to measure Ras-GTP levels directly as done in this report. Bcr-Abl was originally found to be incapable of transforming NIH3T3 cells (Daley et al., 1987) . Furthermore, BcrAbl is known to selectively cause hematopoietic malignancies when expressed in multiple tissues in transgenic mice (Groen et al., 1993; Heisterkamp et al., 1990; Voncken et al., 1992 Voncken et al., , 1995 . Therefore, it is possible that the contrasting conclusions from data generated in NIH3T3 ®broblasts and the hematopoietic cells examined here, re¯ect dierences in Bcr-Abl signaling capabilities in dierent cell types.
The mitogenic signal elicited by Bcr-Abl likely plays a role in the transformation of cells in culture. 32D cells are a useful experimental system to examine Bcr-Abl signaling, but they do not accurately model all aspects of Bcr-Abl-associated leukemias in vivo. The ability of Bcr-Abl to prevent cell cycle exit as demonstrated in 32D cells may also be important in the context of chronic phase CML. The translocation that creates BcrAbl occurs in stem cells which normally proliferate to replenish the hematopoietic tissue. During the chronic phase of CML, an expansion of the leukemic cells occurs which leads to an approximately 5 ± 10-fold increase in total hematopoietic cell mass (Clarkson and Strife, 1993) . While these cells do not have an increased proliferative rate, they do undergo extra cell divisions and have longer survival times than normal myeloid progenitors (Athens et al., 1965; Chervenick and Boggs, 1968; Clarkson and Strife, 1993; Galbraith and Abu-Zahra, 1972; Goto et al., 1982; Ogawa et al., 1970; Scott et al., 1971; Strife and Clarkson, 1988; Stryokmans et al., 1977) . Mitogenic signals from Bcr-Abl may serve to inhibit cell cycle exit that would normally occur during the dierentiation process. Therefore, Bcr-Abl-mediated stimulation of mitogenesis, together with prolongation of cell survival and reduction of adhesion dependence, may cause the expansion of the myeloid compartment during the chronic phase of CML.
Blast crisis in CML patients is believed to be caused by the accumulation of additional chromosomal abnormalities and mutations. A wide variety of mutations and chromosomal abnormalities can occur at the blast phase transition, and no single mutation besides the Philadelphia chromosome appears to be required for blast crisis. The acute phase of CML may be caused by mutations and chromosomal abnormalities that augment a Bcr-Abl-initiated mitogenic signal. These secondary mutations may activate growth promoting pathways to cooperate with Bcr-Abl, or inactivate negative regulatory pathways that act in opposition to Bcr-Abl signaling.
In conclusion, our data demonstrate that Bcr-Abl activates mitogenic signaling pathways which result in a decreased requirement for growth factors. Thus, BcrAbl is a multi-functional tyrosine kinase that derives its transforming activities through activation of multiple intracellular signaling pathways resulting in anchorage independent growth, inhibition of apoptosis and cellular proliferation.
Materials and methods
Cell culture
32D cells were obtained from Dr Jacalyn Pierce (NIH). Cells were maintained in RPMI containing 10% fetal bovine serum (FBS) and 10% WEHI conditioned media (WEHI-CM) as a source of IL-3. Bcr-Abl-transformed 32D cells were produced using retroviral infection. Retroviruses encoding the bcr-abl genes were produced in Bosc-23 cells as previously described (Pear et al., 1993) . Infections were performed in a volume of 1.5 ml in the presence of WEHI-CM as a source of IL-3. Selection was performed with 0.7 mg/ml G418 or by deprivation of IL-3. IL-3 deprivation was performed by washing the cells twice with RPMI and resuspending at a concentration of approximately 10 5 cells/ml. Expression of Bcr-Abl was con®rmed by immunoblotting.
32D cells that inducibly express Bcr-Abl were produced by electroporation of pJ5O-Bcr-Abl vector (50 mg) with pBABEpuro vector (0.5 mg). The pJ5O vector expresses proteins conditionally from a glucocorticoid responsive promoter (Morgenstern and Land, 1990) . Two days after transfection the cells were suspended in RPMI containing 10% charcoalstripped FBS (Gemini Bioproducts) and 10% WEHI-CM supplemented with 1 mg/ml puromycin. These cells were cloned by limiting dilution into 96-well plates. Puromycin resistant clones were expanded and screened for Bcr-Abl expression in the presence or absence of 50 nM dexamethasone. Experiments were performed with multiple clones of Bcr-Abl inducible cell lines with no qualitative dierences observed between p210 and p185 signaling. Representative data is shown for brevity.
Starvation conditions for inducing a reversible growth arrest were 1% serum and between 0.1 ± 0.5% WEHI-CM. The actual percentage of WEHI used was determined empirically on each batch of WEHI-CM that was produced. The criteria measured were viability and growth arrest. Aliquots of WEHI-CM were stored at 7808C.
Analysis of Ras activity
The procedure for assaying the percent GTP bound to Ras was performed as reported previously .
Erk and Jnk activity assays
Erk activity was measured in an in vitro immune complex kinase assay. Cells were washed twice with RPMI and starved in RPMI for 1 h. FBS/WEHI-CM (10%/10%) was used to stimulate the cells for 10 min as a positive control for Erk activation. Cells were lysed in HEPES pH 7.5, 100 mM NaCl, 1% NP40, 2 mM EDTA, 1 mM PMSF, 10 mg/ml leupeptin, 10 mg/ml aprotinin, 2 mM sodium pyrophosphate, 25 mM sodium b-glycerophosphate, and 1 mM sodium vanadate. Lysates were clari®ed at 16 000 g for 10 min at 48C. Protein concentrations were determined using the DC Protein Assay kit (BioRad, Inc.) and bovine serum albumin as standards. One-hundred micrograms of lysate protein were immunoprecipitated with anti-Erk1 (C-16, Santa Cruz Biotechnology). Immune complexes were washed two times with lysis buer and two times with 10 mM HEPES pH 7.2, 10 mM MgAcetate. Kinase assays were performed in 10 mM HEPES pH 7.2, 10 mM MgAcetate, 0.5 mg/ml myelin basic protein (Sigma, Inc.), 50 mM ATP and 5 mCi [g-32 P]ATP (3000 Ci/mmol, NEN, Inc.), for 30 min at 308C.
Jnk assays were performed in a solid-phase kinase assay using GstJun (amino acids 1 ± 79) immobilized on glutathione-sepharose. GstJun was puri®ed as described (Smith and Johnson, 1988) . Cells were washed twice with RPMI and starved in RPMI for 1 h. As a control, TNFa (Boehringer Mannheim) was used at 10 ng/mL for 10 min. Cells were lysed in Tris pH 7.4, 137 mM NaCl, 10% glycerol, 1% Triton-X 100 2 mM EDTA pH 7.4, 1 mM PMSF, 10 mg/mL leupeptin, 25 mM sodium b-glycerophosphate pH 7.4, 2 mM sodium pyrophosphate, and 1 mM sodium vanadate. Lysates were clari®ed by centrifugation at 16 000 g for 10 min at 48C. One-hundred micrograms of lysate protein were incubated with 10 mg of GstJun immobilized on glutathione-sepharose in 1 mL of lysis buer for 2 h at 48C. The beads were washed three times with lysis buer and one time with kinase buer containing 25 mM HEPES pH 7.4, 25 mM MgCl, 25 mM bglycerophosphate pH 7.4, 0.1 mM sodium vanadate and 2 mM DTT. The beads were resuspended in kinase buer with 10 mM ATP and 5 mCi [g-32 P]ATP and reactions were carried out for 20 min at 308C. Erk and Jnk kinase reactions were terminated by the addition of 26sample buer, analysed by SDS ± PAGE, and quanti®ed with a phosphorimaging system (Molecular Dynamics, Inc.).
Measurements of cell cycle position and DNA synthesis
Measurement of cell cycle position was determined by¯ow cytometry following staining with propidium iodide. 5 ± 10610 5 cells were ®xed in 70% ethanol for at least 2 h at 48C. The ®xed cells were resuspended in PBS and stained with propidium iodide. Samples were analysed on a Becton Dickenson FACScan.
DNA synthesis was measured by plating 2610 5 viable cells per well of a 24-well dish containing 1 mL of media and 4 mCi [ 3 H]thymidine (NEN). After 2 h incubation, cells were harvested using a Phd cell harvester and total counts measured using a Beckman scintillation counter.
Histone H1 kinase assays
Cyclin dependent kinase (Cdk)-2-associated kinase activity was assayed by a protocol adapted from Ewen et al. (1993) .
Tyrosine kinase signaling to the cell cycle D Cortez et al Cells were lysed in Cdk2 lysis buer (50 mM Tris pH 8.0, 200 mM NaCl, 0.5% NP-40, 1 mM PMSF, 10 mg/mL aprotinin, 10 mg/mL leupeptin, 75 mM NaF, 20 mM bglycerophosphate, 0.4 mM sodium vanadate and 1 mM DTT) for 20 min on ice. Lysates were cleared by centrifugation and normalized for protein concentration using the DC Protein Assay kit (BioRad, Inc.). Immunoprecipitates for Cdk2 were performed using 1 mg of M-20 rabbit polyclonal antibody to Cdk2 (Santa Cruz Biotechnology) and protein-A-agarose. Immunoprecipitates were washed three times with lysis buer and twice with Cdk2 kinase buer (50 nM Tris pH 7.5, 10 mM MgCl 2 , 1 mM DTT). Kinase buer supplemented with 5 mg of histone H1 (Boehringer Mannheim Biochemicals), 20 mM ATP, and 10 mCi of [g-32 P]ATP (3000 Ci/mmol) was added to the immunoprecipitates to a ®nal reaction volume of 50 mL. The reaction was incubated at 308C for 20 min. The reaction was stopped by the addition of SDS sample buer. After boiling, the samples were electrophoresed through a 10% SDS-polyacrylamide gel. The gel was dried and exposed to X-ray ®lm. Samples were quanti®ed on a Molecular Dynamics Phosphorimager.
GST-Rb kinase assays
Cyclin D-associated kinase activity was assayed by an immune complex kinase assay adapted from Matsushime et al. and DeGregori et al. (DeGregori et al., 1995; Matsushime et al., 1994) . Cells were harvested, washed twice in PBS, and resuspended in 1 mL of Rb lysis buer (50 mM HEPES at pH 8.0, 150 mM NaCl, 0.1% Tween 20, 1 mM EDTA, 2 mM EGTA) containing 10% glycerol, 1 mM DTT, 0.1 mM PMSF, 10 mg/mL aprotinin, 1 mM NaF and 0.1 mM sodium orthovanadate per 10 7 cells. Cell lysates were frozen in liquid nitrogen, thawed on ice for 2.5 h and then cleared by centrifugation for 10 min. Total protein in each sample was normalized by the Bradford assay (BioRad). Between 0.5 and 1 mg of total protein was used per immunoprecipitation. The lysates were immunoprecipitated for 3 h at 48C with 3 mg of the indicated antibodies bound to protein A/G-agarose (Santa Cruz Biotechnology). The antibodies used were anti-cyclin D1 (72-13G), anti-cyclin D2 (M-20), or anti-cyclin D3 (18B6-10) from Santa Cruz Biotechnology. Control rat and rabbit IgG was purchased from Zymed and Cappel respectively. The immunoprecipitates were washed four times with Rb lysis buer and twice with Rb kinase buer (50 mM HEPES pH=8.0, 10 mM MgC1 2 ). Kinase reactions were performed in 30 mL of Rb kinase buer containing 2 mg of fresh GST-Rb (described below), 2.5 mM EGTA, 1 mM DTT, 10 mM b-glycerophosphate, 0.1 mM sodium orthovanadate, 1 mM NaF, 20 mM ATP, 2 mM glutathione, and 5 mCi of [g-32 P]ATP (3000 Ci/mmol). Following 30 min incubation at 308C the reactions were stopped by the addition of SDS sample buer. After boiling the samples were electrophoresed through an 8% SDS-polyacrylamide gel, and the dried gel was exposed to X-ray ®lm. Samples were quanti®ed on a phosphorimager.
The GST-Rb substrate (379 ± 926) was prepared as follows. An overnight culture of E. coli transformed with pGEX-Rb (379 ± 926) was diluted 1 : 10 in luria broth and grown at room temperature until an OD 600 of 0.6 ± 0.8 was obtained. 0.5 mM isopropylthioglycoside was added and the cells were incubated overnight at room temperature. Cells were recovered by centrifugation, resuspended in 30 mL of NETN buer (50 mM Tris at pH 7.5, 100 mM NaCl, 1 mM EDTA, 0.5% NP-40) containing 1 mM PMSF. Suspended cells were sonicated on ice four times for 5 s using a microtip sonicator at full power. The lysate was cleared by centrifugation at 9000 r.p.m. for 10 min and then added to 150 mL of 50% slurry of glutathione-sepharose 4B (Pharmacia) which had been equilibrated in NETN buer. The lysate and beads were incubated at 48C for 1 ± 3 h then washed three times with NETN buer and twice with Rb kinsae buer. Finally, the GST-Rb was eluted for 1 ± 3 h at 48C by incubation in 300 ± 500 mL of Rb kinase buer containing a ®nal concentration of 2 mM reduced glutathione. Fresh substrate was prepared for each experiment.
Western immunoblotting
Total cell lysates were analysed by Western blot using antibodies against Abl, cRaf (Transduction Laboratories, Inc.), P-Tyr (PY20, Santa Cruz Biotechnology), and Erk1 (C-16) (Santa Cruz Biotechnology). For cRaf and Erk blots, cells were starved as described for the Erk kinase assays. Total protein was normalized using the DC Protein Assay Kit (BioRad). Horseradish peroxidase-conjugated goat anti-rabbit and goat anti-mouse antibodies (BioRad, Inc.) were used as secondary antibodies. Western blots were developed with the enhanced chemiluminescent system (Amersham, Inc.). Erk shift analyses were performed using a low crosslinking SDS ± PAGE.
